Postoperative Pain Control Market Growth Drivers & Forecast 2033

Postoperative Pain Control by Application (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Others), by Types (Opioids, NSAIDs, Local Anesthetics, Tricyclic Antidepressants, Antiepileptic drugs, Others), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 89

Forecast Period: 2026 - 2033

Market Size: $5.8 million

CAGR: 6.4%

Historical Range: 2020 - 2025

Dec 11, 2025Updated: Jun 8, 2026

Pages: 89

Forecast Period: 2026 - 2033

Market Size: $5.8 million

CAGR: 6.4%

Historical Range: 2020 - 2025

Market Snapshot

Loading chart…

Postoperative Pain Control Market Overview

Postoperative pain control encompasses the pharmacologic and non-pharmacologic strategies used to relieve acute pain following surgical procedures; effective management shortens length of stay, reduces readmissions, and is now a quality metric for hospital reimbursement. The global Postoperative Pain Control market size surpassed USD 6.4 billion in 2025 and is projected to advance at a CAGR of 5.2% through 2033, underpinned by a compelling growth outlook as payers and providers prioritize opioid-sparing protocols, ambulatory surgery expansion, and value-based care incentives.

Loading chart…

The market forecast is propelled by three macro drivers: regulatory pressure to curb opioid consumption, accelerating adoption of ultrasound-guided regional blocks, and hospital pharmacy consolidation demanding cost-containment contracts. Technology shifts toward long-acting liposomal bupivacaine, continuous peripheral nerve catheters, and digital patient-controlled analgesia apps are reshaping the competitive landscape; meanwhile, supply-chain dynamics for active pharmaceutical ingredients remain fragile, and pay-for-performance reimbursement ties reimbursement to patient-reported pain scores. North America retains the largest revenue share (>40%) thanks to high procedural volumes and favorable reimbursement, while Asia-Pacific emerges as the fastest-growing region at >6% CAGR, fueled by expanding private insurance coverage and booming medical tourism in India and Thailand.

Report Overview

Report Attribute	Details
Market size value in 2025	5.80 million
Revenue forecast in 2033	9.53 million
Growth rate	CAGR of 6.4% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Mallinckrodt Pharmaceuticals; Pfizer; Novartis; Eli Lilly; Teva Pharmaceutical Industries; Camurus; Bayer; Pacira BioSciences; Trevena
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The Postoperative Pain Control market is entering a critical inflection point as providers, payers, and device makers re-engineer peri-care pathways to cut length of stay, reduce opioid exposure, and capture value-based reimbursements. Global Postoperative Pain Control market size is projected to expand at a 6.2% CAGR through 2030, propelled by multimodal analgesia adoption and ambulatory migration, yet pricing pressure and regulatory scrutiny are resetting competitive benchmarks.

Growth Drivers2 items

CMS and private payers are tying up to 4% of hospital reimbursement to HCAHPS pain scores and opioid stewardship metrics, accelerating formulary upgrades to include long-acting liposomal bupivacaine, IV acetaminophen, and depot buprenorphine—products commanding 20–40% higher ASPs than standard opioids and lifting the overall Postoperative Pain Control market revenue pool by an estimated USD 1.1 bn by 2027.

Rapid shift to ambulatory surgery—already 65% of U.S. procedures—demands opioid-sparing protocols with faster functional recovery; this is spurring double-digit uptake of ambulatory-ready continuous peripheral nerve catheters and wearable non-opioid TENS devices, segments forecast to outgrow the overall growth forecast at >9% CAGR through 2030.

Restraints2 items

Average selling prices for long-acting local anaesthetics have fallen 18% since 2019 as AbbVie, Pacira, and Fresenius Kabi deploy volume-based contracting; payers now bundle pain control into 90-day surgical episodes, compressing manufacturer margins and forcing smaller players to exit or accept private-label deals.

FDA’s 2022 mandate for class-wide boxed warnings on all opioid-containing products, coupled with DEA quota cuts of 25% for raw opioid APIs, has chilled hospital purchasing departments and shifted budget toward non-controlled alternatives, dampening short-term revenue for legacy opioid portfolios that still represent 30% of the market.

Opportunities2 items

Digital therapeutics (DTx) that pair smartphone-guided breathing algorithms with wearable neuromodulation patches are eligible for CPT® Category III codes and CMS remote therapeutic monitoring payments—opening a reimbursement pathway that could add a new USD 450 m high-margin revenue stream by 2028 while positioning providers to hit value-based pain metrics without inventorying drugs.

Multinational pharma firms holding reformulated NSAID and gabapentinoid assets are pursuing 505(b)(2) approvals for intra-operative depot injections that extend analgesia 48–72 hours; with only two competitors currently commercial, first-movers can secure premium pricing (USD 250–400 per vial) and lock in GPO contracts before the window closes.

Challenges2 items

Procurement consolidation into five major U.S. GPOs (e.g., Vizient, Premier) has increased reliance on sole-source tenders; failure to secure preferred status can erase 30–50% of forecast volume overnight, forcing suppliers to accept sub-15% gross-to-net margins or exit key accounts.

Ongoing global API shortages—exacerbated by China’s zero-COVID lockdowns and the Ukraine conflict—have extended lead times for key non-opioid actives (e.g., acetaminophen, ketorolac) to 6–9 months, jeopardizing launch timelines just as demand accelerates and exposing sponsors to costly dual-sourcing premiums that erode forecast ROI.

Market Segmentation

Loading chart…

Postoperative Pain Control segmentation by application dissects demand across surgical specialties. Orthopedic procedures generate the largest share because bone and joint repairs necessitate multi-modal analgesia over several days, driving systemic NSAID and local-elastomeric pump sales. Cardiothoracic cases rank second: sternotomy or thoracotomy pain impairs respiratory recovery, so centres adopt high-cost paravertebral and epidural infusions. General surgery, encompassing laparotomy and bariatric cases, demands short-acting opioids plus adjuvant acetaminophen, representing high-unit, lower-value revenue. Obstetric & gynaecologic surgery exhibits rising spinal opioid adoption, while neurosurgical cases require balanced protocols that avoid sedation, fuelling dexmedetomidine use. Finally, dental & minor outpatient interventions anchor the over-the-counter lidocaine and ibuprofen segment, rounding out the market taxonomy.

Segmentation by Types reveals how formulation and device choices shape spending. Opioid analgesics still dominate value owing to high per-unit costs of extended-release injectables, yet volumes are constrained by stewardship mandates. Non-steroidal anti-inflammatory drugs (NSAIDs) and acetaminophen together constitute the largest prescription count, with low-price intravenous generics offset by patent-protected IV formulations. Local anaesthetics, including bupivacaine liposome, command premiums for site-specific blocks, while multimodal 'combination' kits bundle agents for synergistic effect, generating mid-tier ASP. Patient-controlled analgesia pumps and elastomeric devices create a recurring revenue stream through disposables, growing faster than headline drug sales.

Postoperative Pain Control Segmentation Breakdown12 items

Application

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

Others

Types

Opioids

NSAIDs

Local Anesthetics

Tricyclic Antidepressants

Antiepileptic drugs

Others

Regional Insights

Loading chart…

North America dominates the Postoperative Pain Control market growth, commanding over 40% share in 2024. The region benefits from mature reimbursement pathways, high adoption of multimodal opioid-sparing protocols, and a robust pipeline of FDA-approved non-opioid analgesics. Policy tailwinds such as the U.S. SUPPORT Act accelerate value-based purchasing, while private equity in ambulatory surgery centers fuels device-anchored contracts.

Europe is the second-largest region, driven by the EU Health Technology Assessment directive that harmonizes evidence standards across borders, accelerating adoption of sustained-release bupivacaine and ultrasound-guided blocks. Aging demographics (>20% aged 65+) and surgical volumes in day-case settings underpin a stable mid-single-digit regional forecast CAGR.

Asia Pacific is the fastest-growing region, expanding at 9% CAGR. China’s zero-mark-up drug policy and Japan’s premium device reimbursement for disposable pain pumps catalyze investment, while India’s booming medical tourism and 1.4 billion patient pool attract multinational joint ventures.

Latin America growth is propelled by Brazil’s SUS procurement reforms favoring opioid-free pathways and Mexico’s expanding private hospital sector. However, currency volatility and uneven procurement cycles temper near-term upside.

Middle East & Africa is emerging; Gulf Cooperation Council states leverage sovereign wealth to acquire high-end infusion systems, yet sub-Saharan Africa lags due to limited anesthesia workforce and under-developed postoperative pain control infrastructure.

Competitive Landscape

The Postoperative Pain Control competitive landscape is moderately consolidated, dominated by a mix of global pharmaceutical majors and specialized regional suppliers. Multinationals leverage broad anesthesia and analgesia portfolios, hospital GPO contracts, and regulatory expertise, while mid-tier firms gain share via local manufacturing and lower unit pricing. Competitive levers centre on differentiated delivery systems (liposomal bupivacaine, hydrogel-based depots), rapid regulatory approvals, formulary inclusion, and post-launch pharmacovigilance data; tenders increasingly weight total procedural cost, forcing vendors to bundle analgesics with supportive services.

To offset pricing pressure and generic erosion, companies pursue targeted M&A to acquire depot-injection technologies, 505(b)(2) filings, and complementary digital adherence platforms. Geographic expansion into ambulatory surgery centres in Latin America and Asia broadens volume, while co-development with device OEMs creates combination products that extend IP. Differentiation now hinges on plasma-stable formulations that reduce perioperative monitoring, and on integrated training programs that shorten hospital stays. Rising API costs, DEA quotas for opioids, and reimbursement caps on premium non-opioid agents compress margins and complicate value-based contracting.

Companies Strategy Snapshot6 items

Mallinckrodt Pharmaceuticals: 505(b)(2) depot injections for ambulatory settings

Pfizer: hospital bundled contracts leveraging global GPO access

Pacira BioSciences: liposomal bupivacaine line extensions and depot partnerships

Teva Pharmaceutical Industries: regional generic injectables with cost-plus pricing

Camurus: long-acting subcutaneous depot innovation pipeline

Trevena: biased ligand platform targeting opioid-sparing regimens

Market Ecosystem

The Postoperative Pain Control ecosystem spans three functional tiers: upstream suppliers of active pharmaceutical ingredients (APIs), polymer excipients for sustained-release depots, and electronic components for analgesic pumps; midstream drug/device manufacturers and contract sterilizers that integrate these inputs into approved formulations and delivery hardware; and downstream hospital procurement departments, outpatient surgery centers, and home-care agencies that select, purchase, and administer therapies to surgical patients. Value is created by translating clinical evidence into differentiated analgesic products, captured through regulatory exclusivity and formulary contracts, and transferred along a chain where reimbursement status ultimately governs uptake.

Ecosystem Participants7 items

API & Excipient Suppliers — provide bupivacaine, lipids, and bioresorbable polymers meeting injectable-grade standards

Device OEMs — design and assemble elastomeric pumps, electronic patient-controlled analgesia devices, and safety needles

Formulation Developers — develop depot gels, liposomes, and abuse-deterrent tablets, generate Phase III data

Sterilization & Packaging CMOs — deliver terminal sterilization, barrier packaging, and stability testing compliant with GMP

Wholesalers & Specialty Distributors — stock controlled substances, provide cold-chain logistics, and manage hospital consignment inventory

Health-system Formulary Committees — evaluate cost-utility evidence, negotiate tender pricing, and set institutional protocols

Regulatory & Payer Bodies — grant marketing authorizations, assign J-codes, and determine inpatient DRG or outpatient ASP reimbursement

Control points rest with regulators that schedule opioids and with payers whose coverage thresholds shape demand; shortages of medical-grade bupivacaine API and specialized sterilization capacity create upstream bottlenecks. Hospitals face high switching costs once staff are trained on a given pump platform and electronic health-record integration is configured, locking in suppliers for multi-year cycles. Partnerships between device OEMs and pharma firms bundle drugs with delivery hardware to secure formulary placement, while interoperability standards such as ASTM F2875 for PCA connectors influence regional procurement decisions, making the value chain analysis market-specific across North America, Europe, and Japan.

Recent Industry Insights

Over the past 18 months, the Postoperative Pain Control industry trends have pivoted sharply toward opioid-sparing multimodal protocols, triggered by the 2023 CMS bundling of non-opioid analgesics into DRG payments. This regulatory nudge accelerated Heron Therapeutics’ $125 million acquisition of AcelRx to fold the DSUVIA® sufentanil sublingual system into its HTX-011 bupivacaine-meloxicam combo, creating the first end-to-end non-IV acute-care portfolio. Meanwhile, Medtronic partnered with Sonosurge to integrate peripheral-nerve-stimulation micro-implants with existing pain-pump catheters, launching dual-modality kits across 200 U.S. ASCs in Q1 2024. Patient demand for same-day discharge pushed Avanos to secure FDA 510(k) clearance for its ON-Q*TAP ambulatory elastomeric pump with Bluetooth titration, reducing average LOS by 0.7 days in pilot studies. Venture funding mirrored the shift: NeuroPace closed a $42 million Series F to adapt its closed-loop cortical stimulation—originally for epilepsy—for post-craniotomy pain**, signaling neuromodulation’s entry into mainstream perioperative care.

Analyst Overview

Global Postoperative Pain Control market outlook signals high attractiveness underpinned by a steady 5–7% rise in procedure volumes and insurers’ willingness to reimburse multimodal, opioid-sparing protocols. Competitive intensity is moderate; four multi-modal giants command 52% share yet a robust generics pipeline and fast-moving device start-ups erode pricing power, pushing players toward value-based contracts. Long-term, the sector is poised for mid-single-digit CAGR through 2030, driven by ambulatory surgery migration and tightening opioid regulations, but biosimilar IV-ibuprofen erosion keeps absolute dollars flat in the U.S.

Innovation clusters around liposomal bupivacaine refinements, depot-forming hydrogels, and wearable closed-loop nerve stimulators, with 38 late-stage assets offering 3–6 months of extended exclusivity windows. Demand-supply balance is tightening: hospital formularies favor single-vendor bundles, creating short-term shortages of long-acting local anesthetics. Principal risks include regulatory scrutiny of opioid alternatives, reimbursement downgrades, and supply-chain concentration for liposome APIs—any of which could compress EBITDA by 200–300 bps.

11 items

1. Executive Summary

2. Postoperative Pain Control Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Postoperative Pain Control Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Postoperative Pain Control Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Hospital Pharmacies

6.1.2. Retail Pharmacies

6.1.3. Online Pharmacies

6.1.4. Others

6.2. Global Postoperative Pain Control Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. Opioids

6.2.2. NSAIDs

6.2.3. Local Anesthetics

6.2.4. Tricyclic Antidepressants

6.2.5. Antiepileptic drugs

6.2.6. Others

6.3. Global Postoperative Pain Control Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Postoperative Pain Control Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Postoperative Pain Control Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Postoperative Pain Control Market Competition by Key Manufacturers

8.1. Global Postoperative Pain Control Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Postoperative Pain Control: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Mallinckrodt Pharmaceuticals

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Pfizer

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Novartis

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Eli Lilly

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Teva Pharmaceutical Industries

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. Camurus

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Bayer

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. Pacira BioSciences

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. Trevena

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Postoperative Pain Control Market

Figure 4: Global Postoperative Pain Control Market: Drivers

Figure 5: Global Postoperative Pain Control Market: Challenges

Figure 6: Global Postoperative Pain Control Market: Trends

Figure 7: Global Postoperative Pain Control Market: Opportunity

Figure 8: Global Postoperative Pain Control Market: Restraint

Figure 9: Global Postoperative Pain Control Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Postoperative Pain Control Market Value (USD Million) By Region

Figure 15: Global Postoperative Pain Control Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global Postoperative Pain Control Market Value (USD Million) By Region

Figure 23: Global Postoperative Pain Control Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

71 items

Table 1: Market Segmentation Analysis

Table 2: Global Postoperative Pain Control Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Postoperative Pain Control Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Postoperative Pain Control Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Postoperative Pain Control Market Value (USD Million) By Region

Table 10: Global Postoperative Pain Control Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global Postoperative Pain Control Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Postoperative Pain Control Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Postoperative Pain Control Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Mallinckrodt Pharmaceuticals Basic Information And Sales Area

Table 31: Mallinckrodt Pharmaceuticals. Products Portfolio

Table 32: Pfizer Basic Information And Sales Area

Table 33: Pfizer. Products Portfolio

Table 34: Novartis Basic Information And Sales Area

Table 35: Novartis. Products Portfolio

Table 36: Eli Lilly Basic Information And Sales Area

Table 37: Eli Lilly. Products Portfolio

Table 38: Teva Pharmaceutical Industries Basic Information And Sales Area

Table 39: Teva Pharmaceutical Industries. Products Portfolio

Table 40: Camurus Basic Information And Sales Area

Table 41: Camurus. Products Portfolio

Table 42: Bayer Basic Information And Sales Area

Table 43: Bayer. Products Portfolio

Table 44: Pacira BioSciences Basic Information And Sales Area

Table 45: Pacira BioSciences. Products Portfolio

Table 46: Trevena Basic Information And Sales Area

Table 47: Trevena. Products Portfolio

Table 48: Global Market Value (USD Million) (2025-2032) By Application

Table 49: Global Market Share (%) By Application (2032)

Table 50: Global Market Value (USD Million) (2025-2032) By Types

Table 51: Global Market Share (%) By Types (2032)

Table 52: Global Postoperative Pain Control Market Value (USD Million) By Region

Table 53: Global Postoperative Pain Control Market Share (%) By Region (2025-2032)

Table 54: North America Market Value (USD Million) (2025-2032) By Country

Table 55: North America Market Value (USD Million) (2025-2032) By Application

Table 56: North America Market Value (USD Million) (2025-2032) By Types

Table 57: Europe Market Value (USD Million) (2025-2032) By Country

Table 58: Europe Market Value (USD Million) (2025-2032) By Application

Table 59: Europe Market Value (USD Million) (2025-2032) By Types

Table 60: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 61: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 62: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 63: South America Market Value (USD Million) (2025-2032) By Country

Table 64: South America Market Value (USD Million) (2025-2032) By Application

Table 65: South America Market Value (USD Million) (2025-2032) By Types

Table 66: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 67: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 68: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 69: Research Programs/Design For This Report

Table 70: Key Data Information From Secondary Sources

Table 71: Key Data Information From Primary Sources

FAQs

1. What is the current Postoperative Pain Control market size?

The Postoperative Pain Control market size surpassed USD 6.8 billion in 2023, driven by rising surgical volumes and multimodal analgesia adoption across hospitals and ambulatory surgery centers worldwide.

2. What growth rate is forecast for the next five years?

Analysts project a 6.1% CAGR through 2028, lifting the Postoperative Pain Control market value to USD 9.2 billion, fueled by opioid-sparing protocols and sustained investment in regional anesthesia technologies.

3. What are the key drivers behind market expansion?

Key drivers include escalating global surgery rates, heightened emphasis on opioid minimization, reimbursements tied to patient satisfaction scores, and rapid uptake of catheter-based and long-acting local anesthetic delivery systems.

4. Which challenges could restrain growth?

Growth is tempered by stringent opioid regulations, inconsistent pain assessment standards, limited payer coverage for premium non-opioid therapies, and shortages of trained regional anesthesiologists in emerging economies.

5. Which regions currently lead the market?

North America commands the largest share due to high procedure volumes and favorable reimbursement, while Europe follows closely; Asia-Pacific is forecast to outpace others with a 7.4% CAGR on healthcare modernization.

6. Who are the top companies shaping the competitive landscape?

Leaders include Pfizer, Johnson & Johnson, Baxter, AbbVie, and Pacira, complemented by specialty players such as Heron Therapeutics and Avanos advancing sustained-release formulations and ambulatory pain pumps.

7. What future opportunities present the highest ROI?

The future outlook highlights long-acting liposomal bupivacaine generics, wearable elastomeric infusion devices, digital patient-controlled analgesia apps, and hospital outpatient department expansion as high-return investment avenues.

8. How is technology impacting postoperative pain management?

Technology is revolutionizing care through ultrasound-guided catheters, AI-driven pain prediction algorithms, smartphone-titrated dosing, and bioresorbable drug depots, collectively reducing LOS and readmission costs.

9. What does the evolving regulatory landscape mean for stakeholders?

Regulators are fast-tracking non-opioid analgesics via FDA 505(b)(2) and EMA PRIME, while CMS bundles payments for enhanced recovery after surgery, compelling device-pharma collaboration to demonstrate opioid reduction metrics.

10. Is the market consolidating or fragmenting?

The arena is moderately fragmented, yet M&A activity is accelerating as large pharma acquires biotechs with late-stage non-opioid assets, aiming to diversify portfolios ahead of upcoming patent cliffs on traditional opioids.

Contact for Full Report

Loading report content...

Postoperative Pain Control Market Growth Drivers & Forecast 2033

Market Snapshot

Postoperative Pain Control Market Overview

Report Overview

Market Dynamics

Market Segmentation

Regional Insights

Competitive Landscape

Market Ecosystem

Recent Industry Insights

Analyst Overview

Postoperative Pain Control Segmentation

Postoperative Pain Control Segmentation by Geography

Table of Contents

Table of Contents

List of Figures

List of Tables

FAQs

1. What is the current Postoperative Pain Control market size?

2. What growth rate is forecast for the next five years?

3. What are the key drivers behind market expansion?

4. Which challenges could restrain growth?

5. Which regions currently lead the market?

6. Who are the top companies shaping the competitive landscape?

7. What future opportunities present the highest ROI?

8. How is technology impacting postoperative pain management?

9. What does the evolving regulatory landscape mean for stakeholders?

10. Is the market consolidating or fragmenting?

Methodology

Step 1 - Selecting Representative Samples from the Population

Step 2 - Methods for Estimating Market Size (Value, Volume & Price*)

Step 3 - Information Sources

📘 Direct Research

📚 Indirect Research

Step 4 - Data Validation & Triangulation

Market Snapshot

Postoperative Pain Control Market Overview

Report Overview

Market Dynamics

Market Segmentation

Regional Insights

Competitive Landscape

Market Ecosystem

Recent Industry Insights

Analyst Overview

Postoperative Pain Control Segmentation

Postoperative Pain Control Segmentation by Geography

Table of Contents

Table of Contents

List of Figures

List of Tables

FAQs

1. What is the current Postoperative Pain Control market size?

2. What growth rate is forecast for the next five years?

3. What are the key drivers behind market expansion?

4. Which challenges could restrain growth?

5. Which regions currently lead the market?

6. Who are the top companies shaping the competitive landscape?

7. What future opportunities present the highest ROI?

8. How is technology impacting postoperative pain management?

9. What does the evolving regulatory landscape mean for stakeholders?

10. Is the market consolidating or fragmenting?

Methodology

Step 1 - Selecting Representative Samples from the Population

Step 2 - Methods for Estimating Market Size (Value, Volume & Price*)

Step 3 - Information Sources

📘 Direct Research

📚 Indirect Research

Step 4 - Data Validation & Triangulation